Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy

Autores
Stella, Flavia; Pedrazzini, Estela Marta; Agazzoni, Mara; Ballester, Oscar; Slavutsky, Irma Rosa
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Multiple myeloma tumor cells demonstrate multiple and often complex genetic lesions as evaluated by standard cytogenetic/FISH studies. Over the past decade, specific abnormalities have been associated with standard or high-risk clinical behavior and they have become strong prognostic indicators. Further, as evidenced by recent randomized clinical trials, the choice of front-line therapy (transplant vs. no transplant, inclusion of novel drugs such as bortezomib, thalidomide, and lenalidomide) may be able to overcome the adverse effect of high-risk genetic lesions.
Fil: Stella, Flavia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Pedrazzini, Estela Marta. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Agazzoni, Mara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Ballester, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Materia
Cytogenetics
Fish
Multiple Myeloma
Therapy
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/42743
Acceder
id CONICETDig_e0f28f5573846b77d1e1e912a5ce0455
oai_identifier_str oai:ri.conicet.gov.ar:11336/42743
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapyStella, FlaviaPedrazzini, Estela MartaAgazzoni, MaraBallester, OscarSlavutsky, Irma RosaCytogeneticsFishMultiple MyelomaTherapyhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Multiple myeloma tumor cells demonstrate multiple and often complex genetic lesions as evaluated by standard cytogenetic/FISH studies. Over the past decade, specific abnormalities have been associated with standard or high-risk clinical behavior and they have become strong prognostic indicators. Further, as evidenced by recent randomized clinical trials, the choice of front-line therapy (transplant vs. no transplant, inclusion of novel drugs such as bortezomib, thalidomide, and lenalidomide) may be able to overcome the adverse effect of high-risk genetic lesions.Fil: Stella, Flavia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Pedrazzini, Estela Marta. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Agazzoni, Mara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Ballester, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaTaylor2015-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/42743Stella, Flavia; Pedrazzini, Estela Marta; Agazzoni, Mara; Ballester, Oscar; Slavutsky, Irma Rosa; Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy; Taylor; Cancer Investigation; 33; 10; 10-2015; 496-5040735-79071532-4192CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.3109/07357907.2015.1080833?journalCode=icnv20info:eu-repo/semantics/altIdentifier/doi/10.3109/07357907.2015.1080833info:eu-repo/semantics/altIdentifier/pmid/26506456info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:43:46Zoai:ri.conicet.gov.ar:11336/42743instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:43:47.012CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
title Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
spellingShingle Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
Stella, Flavia
Cytogenetics
Fish
Multiple Myeloma
Therapy
title_short Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
title_full Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
title_fullStr Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
title_full_unstemmed Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
title_sort Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy
dc.creator.none.fl_str_mv Stella, Flavia
Pedrazzini, Estela Marta
Agazzoni, Mara
Ballester, Oscar
Slavutsky, Irma Rosa
author Stella, Flavia
author_facet Stella, Flavia
Pedrazzini, Estela Marta
Agazzoni, Mara
Ballester, Oscar
Slavutsky, Irma Rosa
author_role author
author2 Pedrazzini, Estela Marta
Agazzoni, Mara
Ballester, Oscar
Slavutsky, Irma Rosa
author2_role author
author
author
author
dc.subject.none.fl_str_mv Cytogenetics
Fish
Multiple Myeloma
Therapy
topic Cytogenetics
Fish
Multiple Myeloma
Therapy
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Multiple myeloma tumor cells demonstrate multiple and often complex genetic lesions as evaluated by standard cytogenetic/FISH studies. Over the past decade, specific abnormalities have been associated with standard or high-risk clinical behavior and they have become strong prognostic indicators. Further, as evidenced by recent randomized clinical trials, the choice of front-line therapy (transplant vs. no transplant, inclusion of novel drugs such as bortezomib, thalidomide, and lenalidomide) may be able to overcome the adverse effect of high-risk genetic lesions.
Fil: Stella, Flavia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Pedrazzini, Estela Marta. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Agazzoni, Mara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Ballester, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
description Multiple myeloma tumor cells demonstrate multiple and often complex genetic lesions as evaluated by standard cytogenetic/FISH studies. Over the past decade, specific abnormalities have been associated with standard or high-risk clinical behavior and they have become strong prognostic indicators. Further, as evidenced by recent randomized clinical trials, the choice of front-line therapy (transplant vs. no transplant, inclusion of novel drugs such as bortezomib, thalidomide, and lenalidomide) may be able to overcome the adverse effect of high-risk genetic lesions.
publishDate 2015
dc.date.none.fl_str_mv 2015-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/42743
Stella, Flavia; Pedrazzini, Estela Marta; Agazzoni, Mara; Ballester, Oscar; Slavutsky, Irma Rosa; Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy; Taylor; Cancer Investigation; 33; 10; 10-2015; 496-504
0735-7907
1532-4192
CONICET Digital
CONICET
url http://hdl.handle.net/11336/42743
identifier_str_mv Stella, Flavia; Pedrazzini, Estela Marta; Agazzoni, Mara; Ballester, Oscar; Slavutsky, Irma Rosa; Cytogenetic alterations in multiple myeloma: prognostic significance and the choice of frontline therapy; Taylor; Cancer Investigation; 33; 10; 10-2015; 496-504
0735-7907
1532-4192
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.3109/07357907.2015.1080833?journalCode=icnv20
info:eu-repo/semantics/altIdentifier/doi/10.3109/07357907.2015.1080833
info:eu-repo/semantics/altIdentifier/pmid/26506456
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor
publisher.none.fl_str_mv Taylor
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846782130726633472
score 12.982451

Publicaciones similares